Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.43 |
| ▸ | NCF1 | P14598 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591377 | 0.94 | ADRA2C (0.56) | ADRA2CMAPTGAAKDM4EPTK2B | |
| SCHEMBL15474579 | 0.81 | CHKA (0.45) | ADRA2CMAPTGAAKDM4EPTK2B | |
| SCHEMBL590210 | 0.81 | GAA (0.51) | MAPTGAAKDM4EGFERADORA2A | |
| SCHEMBL589160 | 0.77 | LMNA (0.59) | MAPTMAPK1ALDH1A1CHKALMNA | |
| SCHEMBL215829 | 0.76 | NCF1 (0.58) | ADRA2CMAPTGAAKDM4EPTK2B | |
| SCHEMBL17728862 | 0.76 | GAA (0.56) | ADRA2CMAPTGAAKDM4EGFER | |
| SCHEMBL30565926 | 0.76 | MAPT (0.65) | ADRA2CMAPTGAAKDM4EPTK2B | |
| SCHEMBL3935104 | 0.76 | MAPT (0.65) | ADRA2CMAPTGAAKDM4EPTK2B | |
| SCHEMBL2649456 | 0.76 | ADRA2C (0.86) | ADRA2CMAPTGAAKDM4EPTK2B | |
| SCHEMBL5884761 | 0.75 | HTR3A (0.51) | ADRA2CMAPTGAAKDM4EPTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120932-B1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-07-09 | — | — | EP | disclosed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| EP-2120932-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074749-A9 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008074749-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | MAP3K5, MAP3K19, MAP3K3 | ADRA2C 2337/4885MAPT 2569/4885GAA 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.